↓ Skip to main content

New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016

Overview of attention for article published in Journal for Immunotherapy of Cancer, June 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (96th percentile)
  • High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news
8 news outlets
twitter
17 X users
patent
1 patent
facebook
2 Facebook pages

Citations

dimensions_citation
11 Dimensions

Readers on

mendeley
40 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016
Published in
Journal for Immunotherapy of Cancer, June 2017
DOI 10.1186/s40425-017-0253-2
Pubmed ID
Authors

Prasad S. Adusumilli, Edward Cha, Mark Cornfeld, Thomas Davis, Adi Diab, Thomas W. Dubensky, Elizabeth Evans, Jane L. Grogan, Bryan A. Irving, Rom S. Leidner, Shane A. Olwill, Patrick Soon-Shiong, Frederic Triebel, David Tuck, Adrian Bot, Roger D. Dansey, Charles G. Drake, Gordon J. Freeman, Ramy Ibrahim, Salil Patel, Daniel S. Chen

Abstract

This report is a summary of 'New Cancer Immunotherapy Agents in Development' program, which took place in association with the 31st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), on November 9, 2016 in National Harbor, Maryland. Presenters gave brief overviews of emerging clinical and pre-clinical immune-based agents and combinations, before participating in an extended panel discussion with multidisciplinary leaders, including members of the FDA, leading academic institutions and industrial drug developers, to consider topics relevant to the future of cancer immunotherapy.

X Demographics

X Demographics

The data shown below were collected from the profiles of 17 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 40 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 40 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 8 20%
Student > Bachelor 5 13%
Student > Ph. D. Student 3 8%
Professor > Associate Professor 3 8%
Professor 2 5%
Other 6 15%
Unknown 13 33%
Readers by discipline Count As %
Immunology and Microbiology 7 18%
Pharmacology, Toxicology and Pharmaceutical Science 4 10%
Medicine and Dentistry 4 10%
Agricultural and Biological Sciences 3 8%
Biochemistry, Genetics and Molecular Biology 3 8%
Other 5 13%
Unknown 14 35%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 79. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 August 2022.
All research outputs
#540,616
of 25,382,440 outputs
Outputs from Journal for Immunotherapy of Cancer
#115
of 3,422 outputs
Outputs of similar age
#11,521
of 330,053 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#2
of 21 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,422 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.4. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 330,053 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.